. Author manuscript; available in PMC: 2016 Jan 5.

Published in final edited form as: Nat Rev Clin Oncol. 2014 Sep 30;11(11):637–648. doi: 10.1038/nrclinonc.2014.159

Table 3.

Toxin immunoconjugates in development

Agent	Diseases treated	Toxin	Linker	Antibody type	Developmental stage
260F9104,105	Breast cancer	Ricin A	Internally cleaved	Mouse monoclonal IgG1 targeting Mr 55,000 breast cancer antigen	Not pursued due to toxicity

Moxetumomab pasudotox¹¹⁰	Relapsed/refractory hairy-cell leukaemia Relapsed/refractory ALL ALL/NHL	Pseudomonas exotoxin A	Internally cleaved	Fv antibody fragment targeting CD-22	Phase III trial Phase I/II trial Phase I trial

SS1P⁵⁵	Mesothelioma	Pseudomonas exotoxin A	Internally cleaved	Fv antibody fragment targeting mesothelin	Early phase trials

Abbreviations: ALL, acute lymphocytic leukaemia; NHL, non-Hodgkin lymphoma.